Viventia Biotech Inc.

Clinical Development

Viventia Biotech is focused on the discovery and development of a new generation of advanced monoclonal antibody products that may offer safer, more beneficial therapies for those who suffer from cancer.

Viventia Biotech’s monoclonal antibody portfolio has significant therapeutic potential for the treatment of many of the most common cancers including cancers of the bladder, breast, colon, head & neck, kidney, liver, lung, ovary, pancreas, prostate and skin.